At the NYCneuromodulation 2013 conference, Soterix Medical Inc. , Rogue Resolutions Ltd, and neuroConn GmbH announced the revolutionary MOBILE neuromodulation platform. The product represents yet another collaboration between Soterix Medical Inc. (based in New York City, NY), Rogue Resolutions Ltd (based in Cardiff, UK), and neuroConn (based in Ilmenau, Germany). Leveraging over five years of engineering innovations, the MOBILE neuromodulation system is the first non-invasive brain stimulation device designed for high-throughput clinical trials and potential home use. The MOBILE stimulator is equipped with proprietary tDCS-Limited Total Energy (LTE) technology, which is the only technology optimized for low-energy neuromodulation.
Each patient receives a customized EASYstrap head-gear with an integrated MOBILE-stimulator. Compliance and safety is achieved through serial distribution of patient MOBILE-kits, each including: 1) A discharge-key that enables the MOBILE-stimulator and is programmed to provide 5 (five) timed sessions of therapy consistent with investigational treatment protocols, 2) Accessory packs including 5 (five) pairs of EASYfit or High-Definition electrodes ensuring consistent therapy thereby removing potential for patient error. Exclusive online MOBILE-smart analysis ensures proper set-up and use. Discharge-keys are cloud enabled allowing remote physician supervision.
When compliance and safety cannot be compromised, MOBILE Neuromodulation is the only system with fully integrated electrodes, head-gear, and MOBILE-smart electronics ensuring rigorous and consistent protocols. A system that is sufficiently advanced from any prior device; it could only be developed by the industry leaders in non-invasive neuromodulation. Ideal for extended trials and maintenance phases, the MOBILE device is expected to be deployed into major clinical trials throughout 2014.
Dr. Abhishek Datta, CTO of Soterix Medical summarizes “In forming this partnership with Rogue Resolutions and neuroConn, an industry leader in neuromodulation engineering, Soterix Medical reaffirms its mission to provide clinical researchers and patients with the most advanced and tested brain stimulation technology. The MOBILE system was designed to consider every eventuality in large-scale clinical trials and set-up. This is a complete system from patient set-up, to use, to cloud based compliance monitoring. The next generation EASYstrap customized to work with the MOBILE is the most robust and simple head-gear we have designed. Patients receive controlled supplies of electrodes and discharge-keys that are pre-programmed while the MOBILE stimulator includes the most intelligent monitoring systems available to ensure proper set-up. The stimulator itself has just one button. Tremendous sophistication reduced to unmatched usability. ”
BACKGROUND: tDCS- Limited Total Energy (tDCS-LTE) is an exclusive neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, tDCS-LTE is the only tDCS technology platform optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is under investigation in susceptible populations including stroke, pediatric, traumatic brain injury, etc. tDCS-LTE is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS. Soterix Medical tDCS-LTE is the only non-invasive neuromodulation technology further optimized for robust deployment in a wide variety of environments including emergency medicine, field-work, home-use, etc.
CAUTION: Investigational device. Federal (or United States) law limits device to investigational use.
See full press release here.